Integrated Biopharma Inc: net income or loss
Integrated Biopharma net income or loss: $808.0 thousand for the year ending 2025-06-30, up 621.4% on the year. 15 values since 2011 from SEC filings.
All Integrated Biopharma Inc financial histories
At a glance
Integrated Biopharma reported net income or loss of $808.0 thousand for the year ending 2025-06-30, up 621.4% from $112.0 thousand a year earlier. Across the last five reported years it ranged from -$34.0 thousand (2023-06-30) to $8.01 million (2021-06-30).
Computed from the values in the table below, in USD; each links to the filing it came from.
What this measure means
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
Exact concept: us-gaap:NetIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-07-01 to 2025-06-30. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-07-01 | 2025-06-30 | 808,000 | USD | 2025-09-23 | 10-K · 0001437749-25-029711 SEC |
| 2023-07-01 | 2024-06-30 | 112,000 | USD | 2025-09-23 | 10-K · 0001437749-25-029711 SEC |
| 2022-07-01 | 2023-06-30 | -34,000 | USD | 2024-09-20 | 10-K · 0001437749-24-029768 SEC |
| 2021-07-01 | 2022-06-30 | 3,838,000 | USD | 2023-09-15 | 10-K · 0001437749-23-026022 SEC |
| 2020-07-01 | 2021-06-30 | 8,013,000 | USD | 2022-09-13 | 10-K · 0001437749-22-022334 SEC |
| 2019-07-01 | 2020-06-30 | 4,108,000 | USD | 2021-09-02 | 10-K · 0001437749-21-021375 SEC |
| 2018-07-01 | 2019-06-30 | 1,688,000 | USD | 2020-09-23 | 10-K · 0001437749-20-020123 SEC |
| 2017-07-01 | 2018-06-30 | 679,000 | USD | 2019-08-29 | 10-K · 0001437749-19-017611 SEC |
| 2016-07-01 | 2017-06-30 | 2,346,000 | USD | 2018-09-12 | 10-K · 0001437749-18-016922 SEC |
| 2015-07-01 | 2016-06-30 | 958,000 | USD | 2017-09-01 | 10-K · 0001437749-17-015520 SEC |
| 2014-07-01 | 2015-06-30 | 735,000 | USD | 2016-09-02 | 10-K · 0001437749-16-038298 SEC |
| 2013-07-01 | 2014-06-30 | 131,000 | USD | 2015-09-04 | 10-K · 0001016504-15-000010 SEC |
| 2012-07-01 | 2013-06-30 | 93,000 | USD | 2014-09-08 | 10-K · 0001016504-14-000008 SEC |
| 2011-07-01 | 2012-06-30 | -2,713,000 | USD | 2013-09-30 | 10-K · 0001016504-13-000011 SEC |
| 2010-07-01 | 2011-06-30 | -2,281,000 | USD | 2012-10-15 | 10-K · 0001016504-12-000022 SEC |
Related INTEGRATED BIOPHARMA INC histories
Inspect the source
- Entity
- INTEGRATED BIOPHARMA INC / CIK 0001016504
- Captured
- SEC response SHA-256
f9ec590a908b38ef1a59595c204a1a8d2ad866020a5c8107d7a41fc708faf496
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001016504.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))